Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, TD Cowen Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by equities researchers at TD Cowen from $880.00 to $960.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s target price would suggest a potential upside of 26.15% from the stock’s previous close.

Several other research analysts have also recently issued reports on REGN. Oppenheimer reissued an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 target price for the company. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Finally, Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $818.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $14.41 on Thursday, hitting $760.99. The stock had a trading volume of 334,580 shares, compared to its average volume of 728,234. The company’s 50-day moving average is $764.22 and its two-hundred day moving average is $729.68. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The stock has a market cap of $80.45 billion, a price-to-earnings ratio of 18.31, a P/E/G ratio of 1.66 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post 35.2 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 over the last ninety days. 7.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the business. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Board of the Pension Protection Fund purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: U.S. approval: Dupixent (dupilumab) was approved in the U.S. as the first biologic for children aged 2–11 with uncontrolled chronic spontaneous urticaria (CSU), widening pediatric use and adding a new, addressable patient population for a flagship product with strong pricing and durability. Dupixent U.S. Approval
• Positive Sentiment: EU approval: The European Commission also approved Dupixent for moderate to severe CSU in children 2–11, further enlarging the Dupixent franchise’s geographic and pediatric footprint — a revenue tail that supports longer-term growth expectations. Assessing REGN Valuation After New Dupixent Approval In Europe
• Positive Sentiment: Late?stage pipeline win: Cemdisiran (siRNA) showed rapid, deep and sustained disease control in a Phase 3 gMG trial (NIMBLE); Regeneron submitted a U.S. regulatory application. If approved, cemdisiran could be a first-in-class siRNA for gMG, adding meaningful pipeline value. Cemdisiran Phase 3 Results
• Positive Sentiment: Analyst backing: Cantor Fitzgerald reaffirmed an “overweight” rating and set an $800 price target, signaling analyst confidence and providing a near?term valuation anchor (they note ~4.7% upside from the then?current price). This can bolster investor sentiment and buying interest. Cantor Fitzgerald Rating
• Neutral Sentiment: Earnings outlook: Multiple previews (Zacks, Yahoo) highlight expectations for EPS growth and a possible earnings beat, which could support near?term moves around Regeneron’s report but are not new fundamental catalysts on their own. Regeneron Earnings Preview (Zacks)
• Neutral Sentiment: Investor outreach: Management will present at upcoming BofA and Goldman Sachs healthcare conferences (May–June), offering opportunities for additional pipeline and commercial updates but no immediate new data. Investor Conference Presentations
• Neutral Sentiment: Pipeline detail available: A Seeking Alpha transcript reviews Regeneron’s C5 complement program (cemdisiran + pozelimab) — useful for deeper technical read of the program but not a single?day mover absent new data or filings. C5 Complement Program Transcript
• Negative Sentiment: Stock performance context: Despite the approvals and pipeline wins, longer?term sentiment is mixed — coverage pieces note a year?to?date share price decline, which suggests some investors remain cautious on valuation and growth sustainability. Valuation/Performance Note

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.